XYXiangru Ye

Xiangru Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiangru Ye has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Caihua Xi

    Department of Neurosurgery & Neurocritical Care, Huashan Hospital Fudan University Shanghai China

    1 shared publication
  • Haijun Yao

    Department of Neurosurgery & Neurocritical care, Huashan Hospital Fudan University, Shanghai, China

    1 shared publication
  • Jialin Jin

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

    1 shared publication
  • Jian Yu

    Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China

    1 shared publication
  • Jianhong Zhu

    Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, National Key Laboratory for Medical Neurobiology, Institutes of Brain Science, Shanghai Key Laboratory of Brain Function and Regeneration, Institute of Neurosurgery, MOE Frontiers Center for Brain Science, Shanghai, China

    1 shared publication
  • Jiaxin Xu

    Endoscopy Centre and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Global Burden, Trends, and Inequalities of Clostridioides difficile Infections from 1990 to 2021 and Projections to 2040: A Systematic Analysis

    by Zhihui Chen, Jing Wu, Xiangru Ye, Jialin Jin, Wenhong Zhang

    Background: Clostridioides difficile infection (CDI) poses substantial clinical and economic challenges worldwide. This study aimed to evaluate the global burden, trends, and inequalities of CDI from 1990 to 2021, with projections extending to 2040. Methods: We conducted a systematic analysis of the Global Burden of Disease Study 2021 data for 204 countries and territories. CDI-related mortality and disability-adjusted life years (DALYs) were analyzed from 1990 to 2021. Joinpoint regression assessed the trends, a decomposition analysis identified the contributing factors, and cross-country inequalities were measured with slope and concentration indices. A log-linear age–period–cohort model projected future burden to 2040. Results: Global CDI-related deaths increased from 3047 (95% uncertainty interval [UI], 2550–3609) in 1990 to 15,598 (95% UI, 13,418–18,222) in 2021. The age-standardized mortality rate rose from 0.10 to 0.19/100,000 population (average annual percent change [AAPC], 2.26%; 95% confidence interval [CI], 1.77–2.76%), and the age-standardized DALY rate increased from 1.83 to 3.46/100,000 (AAPC, 1.94%; 95% CI, 1.43–2.45%). Epidemiological changes were the primary driver of this burden, contributing 45.46%. Inequalities were intensified, particularly in high sociodemographic index countries, evidenced by increases in the slope index from 2.00 to 4.17 and concentration index from 0.52 to 0.69. The projections suggest that mortality and DALY rates among populations aged ≥80 years will continue to rise through 2040. Conclusions: The global CDI burden has increased significantly over three decades, disproportionately affecting high sociodemographic index countries. The projected rise in CDI burden among older adults through 2040 underscores the urgent need for targeted interventions and strategic planning.


  • Apelin-Overexpressing Neural Stem Cells in Conjunction with a Silk Fibroin Nanofiber Scaffold for the Treatment of Traumatic Brain Injury

    by Tianwen Li, Qisheng Tang, Jiaxin Xu, Xiangru Ye, Kezhu Chen, Junjie Zhong, Jianhong Zhu, Shijun Lu, Tongming Zhu

    Traumatic brain injury (TBI), especially moderate or severe TBI, is one of the most devastating injuries of the nervous system, as the existing therapies for neurological defect repair have difficulty achieving satisfactory results. Neural stem cells (NSCs) therapy is a potentially effective treatment option, especially after specific genetic modifications and when used in combination with biomimetic biological scaffolds. In this study, tussah silk fibroin scaffolds with interconnected nanofibrous structures were fabricated using a top-down method. We constructed the apelin-overexpressing NSCs that were cocultured with a tussah silk fibroin nanofiber scaffold (TSFNS) that simulated the extracellular matrix (ECM) in vitro. To verify the therapeutic efficacy of engineered NSCs in vivo, we constructed TBI models and randomized the C57BL/6 mice into three groups: a control, NSC-ctrl group (transplantation of NSCs integrated on TSFNS), and NSC-apelin group (transplantation of apelin-overexpressing NSCs integrated on TSFNS). The neurological functions of the model mice were evaluated in stages. Specimens were obtained 24 days after transplantation for immunohistochemistry, immunofluorescence and western blot (WB) experiments, and statistical analysis was performed. The results showed that the combination of the TSFNS and apelin overexpression guided extension and promoted the proliferation and differentiation of NSCs both in vivo and in vitro. Moreover, the transplantation of TSFNS-NSCs-Apelin reduced lesion volume, enhanced angiogenesis, inhibited neuronal apoptosis, reduced blood-brain barrier (BBB) damage, and mitigated neuroinflammation. In summary, TSFNS-NSC-Apelin therapy could build a microenvironment that is more conducive to neural repair to promote the recovery of injured neurological function.


  • Open Access

    Prevalence and Clinical Characteristics of Bacterial Pneumonia in Neurosurgical Emergency Center Patients: A Retrospective Study Spanning 13 Years at a Tertiary Center

    by Weijian Yang, Haijun Yao, Caihua Xi, Xiangru Ye, Qifang Chen, Jun Zhang, Jian Yu, Jin Hu

    Patients with brain injuries are at a heightened susceptibility to bacterial pneumonia, and the timely initiation of empiric antibiotic treatment has been shown to substantially reduce mortality rates. Nevertheless, there is a need for knowledge regarding the resistance and prevalence of pulmonary bacterial infections in this patient population. To address this gap, a retrospective study was conducted at a neurosurgical emergency center, focusing on patients with brain injuries. Among the entire patient population, a total of 739 individuals (18.23%) were identified as having bacterial pneumonia, consisting of 1489 strains of Gram-negative bacteria and 205 strains of Gram-positive bacteria. The resistance of Klebsiella pneumoniae to imipenem exhibited a significant increase, rising from 21.74% in 2009 to 96.67% in 2018, and subsequently reaching 48.47% in 2021. Acinetobacter baumannii displayed resistance rates exceeding 80.0% against multiple antibiotics. The resistance profile of Pseudomonas aeruginosa was relatively low. The proportion of Staphylococcus aureus reached its peak at 18.70% in 2016, but experienced a decline to 7.83% in 2021. The abundance of Gram-negative bacteria exceeded that of Gram-positive bacteria by a factor of 5.96. Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus are prominent pathogens characterized by limited antibiotic choices and scarce treatment alternatives for the isolated strains.